Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1465764 | 0.80 | KIF11 (0.34) | KEAP1NFE2L2CYP2A6KDRKDM4E | |
| SCHEMBL2935635 | 0.80 | KEAP1 (0.47) | KEAP1NFE2L2CYP2A6ALDH1A1GAA | |
| SCHEMBL32889381 | 0.80 | KEAP1 (0.50) | KEAP1NFE2L2CYP2A6KDRALDH1A1 | |
| SCHEMBL12475636 | 0.80 | KEAP1 (0.50) | KEAP1NFE2L2CYP2A6KDRALDH1A1 | |
| SCHEMBL370588 | 0.80 | KEAP1 (0.50) | KEAP1NFE2L2CYP2A6KDRALDH1A1 | |
| SCHEMBL2535316 | 0.77 | KEAP1 (0.51) | KEAP1NFE2L2KDRALDH1A1GAA | |
| SCHEMBL296024 | 0.77 | KEAP1 (0.47) | KEAP1NFE2L2CYP2A6KDRALDH1A1 | |
| SCHEMBL22889556 | 0.77 | GAA (0.47) | KEAP1NFE2L2CYP2A6ALDH1A1GAA | |
| SCHEMBL12822231 | 0.77 | MPO (0.44) | KEAP1NFE2L2CYP2A6KDRALDH1A1 | |
| SCHEMBL4424885 | 0.76 | NQO2 (0.57) | KEAP1NFE2L2CYP2A6ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179087-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | Immunophage Biotech (Shanghai) Co., Ltd. (CN) | 2025-06-05 | — | — | US | disclosed |
| CN-119403800-A | Compounds and their use as LPAR5 antagonists | 艾美斐生物医药科技(上海)有限公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-4486742-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | IMMUNOPHAGE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023165591-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | IMMUTHER PHARMATECH (SHANGHAI) CO., LTD. (CN) | 2023-09-07 | — | — | WO | disclosed |
| EP-3763710-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | Kala Pharmaceuticals, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| WO-2017098421-A1 | BENZOTHIADIAZINE COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| CN-104725381-A | Growth factor receptor inhibitor and application thereof | NANJING SANHOME PHARMACEUTICAL CO LTD | 2015-06-24 | — | — | CN | disclosed |
| EP-2194787-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | Curis, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20090076044-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090076044-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | HENNEQUIN LAURENT FRANCOIS ANDRE | 2008-12-18 | — | — | US | disclosed |
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | HENNEQUIN LAURENT FRANCOIS ANDRE | 2008-12-18 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| CN-1315822-C | Quinoline derivatives having VEGF inhibiting activity | STRAZENECA AB (SE) | 2007-05-16 | — | — | CN | disclosed |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
| CN-1446212-A | Quinoline derivatives having VEGF inhibiting activity | STRAZENECA AB (SE) | 2003-10-01 | — | — | CN | disclosed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | VEGFA, FLT1, FLT4 | KEAP1 2605/4885NFE2L2 1665/4885CYP2A6 3057/4885 |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | VEGFA, FLT1, FLT4 | KEAP1 2578/4885NFE2L2 1370/4885CYP2A6 3105/4885 |
| US-20090076044-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | KDR, HDAC1, FLT4 | KEAP1 1235/4885NFE2L2 650/4885CYP2A6 3920/4885 |
| US-20250179087-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | LPAR5, LPAR3, LPAR2 | KEAP1 1332/4885NFE2L2 4575/4885CYP2A6 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.